Love Serenades and New Flings

in Stock Analysis by

By Vitaliy Katsenelson

I sang love serenades for Abbott Labs’ (ABT) stock for a long time. Call me materialistic, but my love for stocks is not ‘til death do us part,’ it is conditional of fundamentals staying intact and of valuation – it has to be undervalued. Abbott Labs’ fundamentals have improved over the last couple of years – it sold its medical device unit to General Electric (GE) at a great premium and it “stole” a stent business from Guidant playing on Boston Scientific’s (BSX) urgent need to close the deal. Abbott’s management have proven the company to be a very shrewd operator. However, Abbott did what any good stock will do at some point (hopefully) – it appreciated and became fully valued. Though I still love the company, I had to say goodbye to Abbott’s stock. Hopefully, I’ll be able to buy it in the future on my terms, at a lower price.

I found a new ‘fling’ – Glaxo Smithkline (GSK) – Abbott’s worthy replacement. GSK reminds me of Abbot’s stock about two years ago: decent (very similar to ABT) growth prospects ahead (earnings growth of about 7-8% a year) further helped by a growing industry, a strong balance sheet, great return on capital of close to 40%, fat 20% plus profit margins, and a competitive moat around its business that rivals the size of Lake Michigan. All that coupled with great valuation of about 14x earnings and 3.3% dividend yield. On top of all that it comes with an added bonus, its dividend is paid in pounds and converted to dollars – if the dollar decline continues (my expectation), its earnings and dividends will rise in US dollars.



  1. I have owned ABT since 1957. It has been a wonderful “work horse” in my portfolio. I believe in it very strongly because in 50 years it has had its ups and downs, but always has moved upward in value. I have talked to you before about this company. I feel you are wrong in leaving this investment. It is one of the very best companies in the drug and medical supply business in the world. I have met the people at Abbott several times, and they are the very best. Thank you, Sincerely, Thomas D. Roberts

  2. Hello Thomas, I remember our conversation. I still believe ABT is a wonderful company, it is just fairly valued as a stock.



  3. Vitaliy, I have held Abbott Stock since 1987. Through many ups and downs, ignoring advice to sell when times were bad, my total return over 20 years has been 269%. In addition, I get a niftly dividend check 4 times a year. ABT has a history of splitting the stock when it reaches $70. Also, when ABT spun off Hospira in 2004, stockholders of record received a chuck of Hospira stock. The 14K worth of HSP I received is now worth 21K. Holding onto ABT may go against Contrarian views; however, to me, it makes sense. Remember, just $15 more to a stock split!

Leave a Reply

Latest from Stock Analysis

Thoughts on iPhone 6s

Writing is a very weird experience for me. Sometimes it feels almost
Go to Top

Sign Up for Articles

Join tens of thousands of readers


Sign Up for Articles

Join tens of thousands of readers